Author: Admin

Developer

Industries that Benefit from Digital Twin Applications

Posted on by Admin 


Image Credit: Science.org


Computer Modeling Experts Explain the Benefits of Digital Twins

A digital twin is a virtual representation of a real system – a building, the power grid, a city, even a human being – that mimics the characteristics of the system. A digital twin is more than just a computer model, however. It receives data from sensors in the real system to constantly parallel the system’s state.

A digital twin helps people analyze and predict a system’s behavior under different conditions. The systems being twinned are typically very complex and require significant effort to model and track.

Digital twins are useful in a wide variety of domains, including supply chains, health care, buildings, bridges, self-driving cars and retail customer personas to improve efficiency and reliability. For example, a warehouse operator can optimize a warehouse’s performance by exploring the response of its digital twin to various material handling policies and equipment without incurring the cost of making actual changes.

Even a wildfire can be represented by a digital twin. Government agencies can predict the spread of the fire and its impact under different conditions such as wind velocity, humidity and proximity to habitats, and use this information to guide evacuations.

Why Digital Twins Matter

Digital twins are often used to model, understand and analyze complex systems where performance, reliability and security of the system are critical. In such systems it is paramount to test any changes, whether planned or unplanned.

In order to accurately test changes to the state of the actual system and the effects of any possible stimulus, the digital twin must accurately represent the physical system in its current state. This requires the digital twin to receive continuous updates from the physical system via fast and reliable communications channels.

Creating and maintaining digital twins often involves vast amounts of data to represent various features of the real system. Collecting and processing this data requires advanced communication and computing technologies. Communication support typically involves high-speed internet connections and wireless networks such as Wi-Fi and 5G. Computational support is typically in the form of servers, either in the cloud or closer to the physical system.

This article was republished with permission from The Conversation, a news site dedicated to sharing ideas from academic experts. It was written by and represents the research-based opinions of Amlan Ganguly, Associate Professor of Computer Engineering, Rochester Institute of Technology and Nalini Venkatasubramanian, Professor of Computer Science, University of California, Irvine.


We and other faculty members at Rochester Institute of Technology and the University of California, Irvine are starting the Center for Smart Spaces Research, a research center sponsored by the National Science Foundation. One of the primary ongoing projects within this center is building the basic technologies for creating digital twins in a variety of applications.


Suggested Reading



Edge Computing Importance to AI Applications

How AI is Shaping the Cybersecurity Arms Race





The Technological Invasion in Cannabis Cultivation

Hedge Funds are Still Hot on SPACs

 

Stay up to date. Follow us:

 

Release – PDS Biotechnology Granted FDA Fast Track Designation for Lead Candidate PDS0101

Posted on by Admin



PDS Biotechnology Granted FDA Fast Track Designation for Lead Candidate PDS0101

Research, News, and Market Data on PDS Biotech


PDS Biotech has been granted Fast Track designation for PDS0101 in combination with KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer

FLORHAM PARK, N.J., June 02, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T cell activating technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). PDS0101 in combination with KEYTRUDA® is being studied in the VERSATILE-002 Phase 2, open-label, multicenter trial for the treatment of recurrent or metastatic HPV16-positive head and neck cancer in collaboration with Merck (known as MSD outside the US and Canada).

The FDA’s Fast Track designation program is designed to aid in the development and to expedite the review of drug candidate applications that could potentially treat serious or life-threatening conditions. In order to receive Fast Track designation, a product must also demonstrate the potential to address an unmet medical need. Treatments granted this designation are given the opportunity to have more frequent meetings and interactions with the FDA throughout the entire drug development and review process, with the goal of moving promising new drugs more rapidly through the process. It also provides the opportunity to submit sections of a New Drug Application (NDA) on a rolling basis, where the FDA may review portions of the NDA as they are received instead of waiting for the entire NDA submission. In addition, Fast Track designated products are eligible for Priority Review at the time of NDA or Biologics License Application submission.

“We are thrilled that the FDA has granted Fast Track designation for PDS0101 in combination with KEYTRUDA®,” said Frank Bedu-Addo, Ph.D., Chief Executive Officer of PDS Biotech. “The HPV-associated head and neck cancer prevalence continues to rise, leaving this affected group with limited treatment options to date. Receiving this designation underscores the potential of the Versamune® platform and the need for a new therapy that may improve outcomes for those with this devastating disease.”

PDS Biotech’s lead candidate, PDS0101, is a T cell HPV-specific immunotherapy delivered subcutaneously that has shown the potential to stimulate high levels of HPV16-specific CD8+ and CD4+ T cells within patients by activating multiple immune pathways. These HPV-specific T cells have been shown to target tumors such as anal, cervical, head and neck, penile, vaginal, vulvar that are caused by HPV16 infection. The incidence of head and neck cancer cases has been increasing steadily over the last 10-15 years and over 90% of HPV-positive head and neck cancers are caused by HPV16.1 In addition to the Phase 2 VERSATILE-002 trial, PDS Biotech is also conducting three additional Phase 2 studies in advanced HPV-associated cancers, locally advanced cervical cancer, and early-stage pre-metastatic HPV-associated oropharyngeal cancer with the National Cancer Institute (NCI), The University of Texas MD Anderson Cancer Center, and Mayo Clinic, respectively.

KEYTRUDA® is a registered trademark of Merck Sharp and Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

1Exploring Roles of HPV16 variants
in head and neck squamous cell carcinoma: current challenges and opportunities, Daniela Cochicho, Rui Gil da Costa, Ana Felix, Virology
Journal, November 2021

About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune® and Infectimune™ T cell activating technology platforms. We believe our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in
vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company’s pipeline products address various cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate and ovarian cancers.

Our Infectimune™ -based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses including long-lasting memory T cell responses. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Forward Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune® and Infectimune™-based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune® and Infectimune™-based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, PDS0101, PDS0203 and other Versamune® and Infectimune™-based product candidates; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Versamune® is a registered trademark and Infectimune™ is a trademark of PDS Biotechnology Corporation.

Investor Contact:
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: pdsb@cg.capital

 


Inflation Sticker Shock to be on Powell Says President

Posted on by Admin


Powell is Told by President that He is the Face of Inflation

President Biden made clear on Tuesday (June 1) that Federal Reserve Board Chairman Jerome Powell is the person responsible for handling the inflation fight. Inflation had hit a 40-year high this year while GDP retreated, yet jobs remain strong. The Fed’s new quantitative tightening and Fed Funds increases run the risk of spurring a recession. The President’s message seems to have been Powell’s in charge of the outcome. The rare meeting between a Fed Open Market Committee (FOMC) chairman and a sitting President would seem to highlight the importance of allowing the nation to understand there’s a separation of powers when it comes to the economy. Biden openly told Powell prior to the closed-door meeting that addressing inflation was his “top priority” and added that his plan “starts with a simple proposition: respect the Fed.” This places Powell in the national spotlight as being the face of whatever comes next.

Biden’s top White House economic adviser, Brian Deese, held a press briefing after the meeting related to the Fed’s mission to reel in price spikes. A reporter asked Deese if he thought the Fed has moved too slowly on inflation. The response takes responsibility away from the White House; Deese said, “what the President is doing is acknowledging and underscoring the pivotal role that the Fed plays institutionally and that monetary policy plays in the process of bringing prices down.”

This is the second effort this week to calm discussions about what has been unfolding economically. The President published an op-ed in the Wall Street Journal on Tuesday. The op-ed discussed inflation as well as the  $2 trillion Build Back Better initiative, which stalled in Congress because of its expected impact on inflation, lowering the high cost of shipping, renewable energy subsidies, a social spending initiative, raising taxes, and deficit reduction. Biden also wrote that “the Federal Reserve has a primary responsibility to control inflation” the 46th President then spoke of his efforts, including releasing oil from the national strategic reserve to lower gas prices.

The annual US inflation rate declined slightly to 8.3% in April after hitting a 40-year annual high of 8.5% in March, according to the CPI report released by the Bureau of Labor Statistics. Meanwhile, a poll released last month by CBS found that 69% of US adults disapprove of Biden’s handling of inflation. Separating oneself in the public’s eye from an economy that is fraught with the kind of risk that voters dislike, or even marrying oneself to strong economies, is what Presidents have done through the years.

Does the intent to show separation suggest the Administration fears there may be a hard landing? Lower inflation and sustainable growth can be considered building back better. The economic pain to get there, timed with the mid-term elections, may be the biggest concern addressed this week.

Let us know what you think, comment under this article on Twitter.

Paul Hoffman

Managing Editor, Channelchek

Suggested Content



Russell Reconstitution – Investors Keeping Their Eye on Fridays in June

Top Priority is Fighting Inflation, Says White House




The Soft Landing Challenge, Fed Chairman Makes No Promises

Small-Cap Insider Buying Ratio Could Mean a Market Bottom is Near


Sources

https://www.whitehouse.gov/build-back-better/

https://www.wsj.com/articles/my-plan-for-fighting-inflation-joe-biden-gas-prices-economy-unemployment-jobs-covid-11653940654?mod=opinion_major_pos6&mod=article_inline

https://nypost.com/2022/05/31/joe-biden-hands-inflation-response-to-jerome-powell/

https://www.washingtonpost.com/us-policy/2022/05/31/inflation-economy-timeline/

https://www.cnsnews.com/blog/michael-w-chapman/cbs-news-poll-51-us-adults-say-biden-incompetent

Stay up to date. Follow us:

 

Release – Schwazze Closes Acquisition of Assets of Urban Health & Wellness, Inc.

Posted on by Admin



Schwazze Closes Acquisition of Assets of Urban Health & Wellness, Inc.

Research, News, and Market Data on Schwazze


DENVER, June 1, 2022 /CNW/ – Schwazze, (OTCQX: SHWZ) (NEO: SHWZ) (“Schwazze” or the “Company”), announced today that it closed the transaction to acquire substantially all the assets of Urban Health & Wellness, Inc. (“Urban”).  The transaction includes the adult use Urban Dispensary, located at West 38th Avenue and Clay Street, in Denver’s vibrant Highlands neighborhood as well as a 7,200 square foot indoor cultivation facility (2,700 square feet of canopy) located in Denver, Colorado. This purchase continues Schwazze’s aggressive expansion in Colorado and brings the Company’s total number of Colorado dispensaries to 23 and grow facilities to four. The acquired assets included state and local retail marijuana and marijuana cultivation licenses supporting the adult use dispensary and indoor cultivation facility acquired in the transaction.

 

“Urban’s strategically located dispensary
and grow facility will be excellent additions to our expanding portfolio of
assets in Colorado.  Delivering our brands and our excellent customer
service into new neighborhoods is a Schwazze hallmark as we continue to go deep
in Colorado and New Mexico.” said Nirup Krishnamurthy, Schwazze’s COO.    

The consideration for the acquisition was US$3.2 million, which was paid $1.3M in cash and $1.9M in Company common stock upon closing, of which $288,000 of this common stock consideration was held back by the Company for indemnification claims. The common stock consideration was  split 65% to 35% between the two equityholders of Urban.   At closing, each equityholder that received common stock consideration was required to execute a standard lock-up agreement providing for limitations on resale of the stock consideration received.  There were no finder’s fees or similar arrangements in connection with the transaction.

Since April 2020, Schwazze has acquired or announced the planned acquisition of 33 cannabis dispensaries as well as seven cultivation facilities and two manufacturing assets in Colorado and New Mexico. In May 2021, Schwazze announced its BioSciences division and in August 2021, it commenced home delivery services in Colorado.

About Schwazze
Schwazze (OTCQX:SHWZ, NEO:SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.  The Company is committed to unlocking the full potential of the cannabis plant to improve the human condition.  Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes.  The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.  Schwazze is passionate about making a difference in our communities, promoting diversity and inclusion, and doing our part to incorporate climate-conscious best practices.  Medicine Man Technologies, Inc. was Schwazze’s former operating trade name.  The corporate entity continues to be named Medicine Man Technologies, Inc.

Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth.

Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “plan,” “will,” “may,”, “predicts,” or similar words. Forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; (v) difficulties in securing regulatory approval to market our products and product candidates; (vi) our ability to successfully execute our growth strategy in Colorado and outside the state, (vii) our ability to consummate the acquisition described in this press release or to identify and consummate future acquisitions that meet our criteria, (viii) our ability to successfully integrate acquired businesses and realize synergies therefrom, (ix) the ongoing COVID-19 pandemic, * the timing and extent of governmental stimulus programs, (xi) the uncertainty in the application of federal, state and local laws to our business, and any changes in such laws, and * out ability to satisfy the closing conditions for the private finding described in this press release. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/schwazze-closes-acquisition-of-assets-of-urban-health–wellness-inc-301558885.html

SOURCE Medicine Man Technologies, Inc.


Tonix Pharmaceuticals (TNXP) – Monkeypox Patent Issuance, Share Buyback, and Data Presentation Attract Attention

Posted on by Admin

Thursday, June 02, 2022

Tonix Pharmaceuticals (TNXP)
Monkeypox Patent Issuance, Share Buyback, and Data Presentation Attract Attention

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-15001 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second half of 2022. Tonix’s rare disease portfolio includes TNX-29002 for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the FDA. Tonix’s infectious disease pipeline includes a vaccine in development to prevent smallpox and monkeypox called TNX-8013, next-generation vaccines to prevent COVID-19, and an antiviral to treat COVID-19. Tonix’s lead vaccine candidates for COVID-19 are TNX-1840 and TNX-18504, which are live virus vaccines based on Tonix’s recombinant pox vaccine (RPV) platform. TNX-35005 (sangivamycin, i.v. solution) is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-IND stage of development. TNX-102 SL6, (cyclobenzaprine HCl sublingual tablets), is a small molecule drug being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the second quarter of 2022. The Company’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL, is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022. Finally, TNX-13007 is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the second quarter of 2022. TNX-1300 has been granted Breakthrough Therapy Designation by the FDA.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Tonix News Attracts Attention.  On June 1, Tonix stock had a significant price gain (21.9%) on volume of 169.2 million shares (compared with average trading volume of about 2.0 million shares).  This follows the issuance of a patent on the company’s monkeypox vaccine and the announcement of a share buyback program.  Also significant is the planned presentation of preclinical data at meeting of American Transplant Congress held June 4 through 8.

Share Buyback Program.  Tonix announced that it has authorized $12.5 million for repurchases of its outstanding stock.  The company reported $140.4 million in cash or $7.50 per share on March 31, 2022, with a market capitalization of only $45.6 million when announced.  At the recent prices, this could repurchase about 2.5 million to 5 million out of the 18.7 million shares outstanding.  We also believe this attracted attention to the stock’s large discount to cash on hand….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Posted on by Admin



Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Research, News, and Market Data on Tonix Pharmaceuticals


CHATHAM, N.J., June 02, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. On June 1, 2022, Tonix received a letter from The Nasdaq Stock Market LLC stating that because Tonix’s shares had a closing bid price at or above $1.00 per share for a minimum of 10 consecutive business days, Tonix’s stock had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2), and the matter is now closed.

About Tonix Pharmaceuticals Holding Corp.1

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022 and interim data expected in the first quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the second quarter of 2022. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the second quarter of 2022. TNX-1300 has been granted Breakthrough Therapy Designation by the FDA. Finally, TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is expected to enter the clinic with a Phase 2 study in the second half of 2022. Tonix’s rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the FDA. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second half of 2022. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox called TNX-801, next-generation vaccines to prevent COVID-19, and a platform to make fully human monoclonal antibodies to treat COVID-19. Tonix’s lead vaccine candidates for COVID-19 are TNX-1840 and TNX-1850, which are live virus vaccines based on Tonix’s recombinant pox live virus vector vaccine platform.

1All
of Tonix’s product candidates are investigational new drugs or
biologics and have not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2022, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Contacts

Jessica Morris (corporate)
Tonix Pharmaceuticals
investor.relations@tonixpharma.com

(862) 799-8599

Olipriya Das, Ph.D. (media)
Russo Partners
Olipriya.Das@russopartnersllc.com

(646) 942-5588

Peter Vozzo (investors)
ICR Westwicke
peter.vozzo@westwicke.com

(443) 213-0505


Release – Kelly to Participate in the Sidoti Virtual Investor Conference

Posted on by Admin



Kelly to Participate in the Sidoti Virtual Investor Conference

Research, News, and Market Data on Kelly


TROY, Mich., June 2, 2022 /PRNewswire/ — Kelly (Nasdaq: KELYA, KELYB), a leading specialty talent solutions provider, today announced it will participate in the Sidoti Virtual Investor Conference on Thursday, June 16, 2022.

Peter Quigley, president and CEO, Olivier Thirot, executive vice president and chief financial officer, and James Polehna, chief investor relations officer and corporate secretary, will participate in virtual one-on-one meetings. A copy of Kelly’s investor presentation is also available at kellyservices.com.

About
Kelly

Kelly Services, Inc. (Nasdaq: KELYA, KELYB) connects talented people to companies in need of their skills in areas including Science, Engineering, Education, Office, Contact Center, Light Industrial, and more. We’re always thinking about what’s next in the evolving world of work, and we help people ditch the script on old ways of thinking and embrace the value of all workstyles in the workplace. We directly employ more than 350,000 people around the world, and we connect thousands more with work through our global network of talent suppliers and partners in our outsourcing and consulting practice. Revenue in 2021 was $4.9 billion. Visit kellyservices.com and let us help with what’s next for you.

KLYA-FIN

ANALYST
& MEDIA CONTACT: 
James Polehna
(248) 244-4586   
james.polehna@kellyservices.com

Cision View original content:
https://www.prnewswire.com/news-releases/kelly-to-participate-in-the-sidoti-virtual-investor-conference-301559691.html

SOURCE Kelly Services, Inc.


The Promise of Reengineered IL-12 to More Safely Kill Cancer Cells

Posted on by Admin 

Victor Segura Ibarra and Rita Serda/National Cancer Institute (Flickr)


‘Masked’ Cancer Drug Stealthily Trains Immune System to Kill Tumors While Sparing Healthy Tissues

Many cancer treatments are notoriously savage on the body. Drugs often attack both healthy cells and tumor cells, causing a plethora of side effects. Immunotherapies that help the immune system recognize and attack cancer cells are no different. Though they have prolonged the lives of countless patients, they work in only a subset of patients. One study found that fewer than 30% of breast cancer patients respond to one of the most common forms of immunotherapy.

This article was republished with permission from The Conversation, a news site dedicated to sharing ideas from academic experts. It was written by and represents the research-based opinions of Aslan Mansurov, Postdoctoral Researcher in Molecular Engineering, University of Chicago Pritzker School of Molecular Engineering.

But what if drugs could be engineered to attack only tumor cells and spare the rest of the body? To that end, my colleagues and I at the University of Chicago’s Pritzker School of Molecular Engineering have designed a method to keep one promising cancer drug from wreaking havoc by “masking” it until it reaches a tumor.

The Promise of IL-12

Cytokines are proteins that can modulate how the immune system responds to threats. One way they do this is by activating killer T cells, a type of white blood cells that can attack cancer cells. Because cytokines can train the immune system to kill tumors, this makes them very promising as cancer treatments.

One such cytokine is interleukin-12, or IL-12. Though it was discovered more than 30 years ago, IL-12 still isn’t an FDA-approved therapy for cancer patients because of its severe side effects, such as liver damage. This is in part because IL-12 instructs immune cells to produce a large amount of inflammatory molecules that can damage the body.

Scientists have since been working to reengineer IL-12 to be more tolerable while retaining its powerful cancer-killing effects.

Masking the Killer

To create a safer version of IL-12, my colleagues and I took advantage of one of the main differences between healthy and cancerous tissue: an excess of growth-promoting enzymes in cancers. Because cancer cells proliferate very rapidly, they overproduce certain enzymes that help them invade the nearby healthy tissue and metastasize to other parts of the body. Healthy cells grow at a much slower pace and produce fewer of these enzymes.

With this in mind, we “masked” IL-12 with a cap that covers the part of the molecule that normally binds to immune cells to activate them. The cap is removed only when it comes into contact with enzymes found in the vicinity of tumors. When these enzymes chop off the cap, IL-12 is reactivated and spurs nearby killer T cells to attack the tumor.

When we applied these masked IL-12 molecules to both healthy and tumor tissue donated by melanoma and breast cancer patients, our results confirmed that only the tumor samples were able to remove the cap. This indicated that masked IL-12 could potentially drive a strong immune response against tumors without causing damage to healthy organs.

We then examined how safe masked IL-12 is by measuring liver damage biomarkers in mice. We found that immune-related side effects typically associated with IL-12 were notably absent in mice treated with masked IL-12 over a period of several weeks, indicating improved safety.

In breast cancer models, our masked IL-12 resulted in a 90% cure rate, while treatment with a commonly used immunotherapy called a checkpoint inhibitor resulted in only a 10% cure rate. In a model of colon cancer, masked IL-12 showed a 100% cure rate.

Our next step is to test the modified IL-12 in cancer patients. While it will take time to bring this encouraging development directly to patients, we believe a promising new treatment is on the horizon.


Suggested Reading



Cancer’s Predator-Prey Relationship with New Treatments and the Immune System

Pros and Cons of FDA Funded in Part by Companies





Axcella Therapeutics (AXLA) NobleCon18 Presentation Replay

Genprex (GNPX) NobleCon18 Presentation Replay

 

Stay up to date. Follow us:

 

Release – PsyBio Therapeutics Initiates Commercial Biosynthetic Based Process Development for Psycho-Targeted and Psychoactive Compounds

Posted on by Admin


PsyBio Therapeutics Initiates Commercial Biosynthetic Based Process Development for Psycho-Targeted and Psychoactive Compounds

Research, News, and Market Data on PsyBio


PsyBio Therapeutics Advances Proprietary
Patent Pending Manufacturing Towards Fully Developed GMP Production Methodology

OXFORD, Ohio and DENVER, June 2, 2022 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (”
PsyBio” or the “Company“), a fully integrated and intellectual property driven biotechnology company developing novel, bespoke psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today reported that it has initiated formal process development for commercially scalable, patent pending manufacturing technology expected to enable Good Manufacturing Practice (“GMP”) production. PsyBio’s manufacturing process utilizes state of the art bioreactor manufacturing technology to facilitate expansion of PsyBio’s portfolio of compounds. This process methodology is another necessary component for the Chemistry, Manufacturing and Controls section (“CMC”) for its therapeutic candidate portfolio Investigational New Drug (“IND”) applications with the United States Food and Drug Administration (“FDA”).

“This latest manufacturing milestone demonstrates PsyBio’s continued progress, maintaining our role as one of the only biotechnology companies in the psychoactive therapeutic sector developing their own compounds,” stated Evan Levine, PsyBio’s Chief Executive Officer. “PsyBio remains committed to developing effective and scalable techniques designed to enhance our ability to produce an ever-growing number of psycho-targeted therapeutic candidates in a rapid and highly cost-efficient approach.”

PsyBio retains the global, exclusive, and perpetual right to license a platform technology enabling rapid generation of tryptamines and related compounds through a biosynthetic process using genetically modified bacteria and has demonstrated the ability to manufacture one of its first promising therapeutic candidates at commercial scale. Commercial purification process development furthers the ability to manufacture compounds with predictable and reproducible purity.

“The mark of successful product development is the ability to transfer technology from the bench to full scale GMP production. PsyBio has been working throughout the COVID-19 pandemic to develop commercial methodology for the manufacture of pipeline compounds using biotechnology. The initiation of GMP process development is an important step leading to clinical trial initiation,” stated Michael Spigarelli, MD, PhD, MBA, PsyBio’s Chief Medical Officer. “This is expected to allow us to reliably produce predictably pure drug product for clinical evaluation in order to determine its ability to potentially improve mental and neurological health.”

About PsyBio Therapeutics Corp.

PsyBio is an intellectual property driven biotechnology company developing new, bespoke, fully approved, psycho-targeted therapeutics to potentially improve mental and neurological health. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof. The Company utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon which to develop precursors and analogs, both naturally and non-naturally occurring, specifically because they are already known to have an effect within the brain.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking information” (“forward-looking information”) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. Forward looking-statements in this press release include statements regarding: the impact of this manufacturing process achievement on the CMC section of PsyBio’s IND application with the FDA; the impact of this manufacturing process achievement on GMP production; PsyBio’s ability to develop compounds more readily and rapidly than competitive methods; PsyBio’s plans for filing IND applications with the FDA; PsyBio’s ability to develop novel formulations to potentially treat neurologic and psychologic conditions and other disorders; PsyBio’s plans to move towards clinical trials for psycho-targeted therapeutics intended to potentially improve mental and neurological health; PsyBio’s ability to launch clinical trials; PsyBio’s ability to build its intellectual property portfolio of novel drug candidates; PsyBio’s ability to achieve cost competitive synthesis with reduced environmental impact over current production methods; and PsyBio’s ability to move target candidates into scaled commercial manufacturing and regulatory application.

In disclosing the forward-looking information contained in this press release, the Company has made certain assumptions, including that: this manufacturing process will enable GMP production and will help facilitate expansion of PsyBio’s portfolio of compounds; this manufacturing process will have a positive impact on progress toward the filing of IND applications with the FDA; PsyBio will receive approval from the FDA to launch clinical trials; PsyBio will be successful in protecting its intellectual property; PsyBio will be successful in discovering new valuable target molecules; PsyBio will be successful in submitting IND applications and will be able to obtain all necessary approvals for clinical trials; the results of preclinical safety and efficacy testing will be favourable; PsyBio’s technology will be safe and effective; a confirmed signal will be identified in PsyBio’s selected indications; and that drug development involves long lead times, is very expensive and involves many variables of uncertainty. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, it can give no assurance that the expectations of any forward-looking information will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Such factors include, but are not limited to: compliance with extensive government regulations; domestic and foreign laws and regulations adversely affecting PsyBio’s business and results of operations; decreases in the prevailing process for psilocybin and nutraceutical products in the markets in which PsyBio operates; and the impact of COVID-19; and general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.

PsyBio makes no medical, treatment or health benefit claims about PsyBio’s proposed products. The FDA or other similar regulatory authorities have not evaluated claims regarding psilocybin and other next generation psychoactive compounds. The efficacy of such products has not been confirmed by FDA-approved research. There is no assurance that the use of psilocybin and other psychoactive compounds can diagnose, treat, cure, or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. PsyBio has not conducted clinical trials for the use of its intellectual property. Any references to quality, consistency, efficacy and safety of potential products do not imply that PsyBio verified such in clinical trials or that PsyBio will complete such trials. If PsyBio cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the PsyBio’s performance and operations.

The TSX Venture Exchange (the
“TSXV”) has neither approved nor disapproved the contents of this
news release. Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility for the
adequacy or accuracy of this release.

SOURCE PsyBio Therapeutics Corp.

 


Release – Comtech Strengthens Leadership Team for Its U.S. Based Satellite-Focused Business Line

Posted on by Admin



Comtech Strengthens Leadership Team for Its U.S. Based Satellite-Focused Business Line

Research, News, and Market Data on Comtech Telecommunications


Appointments
of New Divisional Chief Operating Officer and General Manager Lend Deep
Communications & Defense Experience to Comtech

MELVILLE, N.Y.–(BUSINESS WIRE)–Jun. 2, 2022– June 2, 2022– Comtech Telecommunications Corp. (NASDAQ: CMTL), a leading global provider of next-generation 911 emergency systems and secure wireless communications technologies, announced today that it has appointed a new divisional Chief Operating Officer (COO) in Jon Opalski and created a new General Manager of Digital Products position that will be filled by Bob Pescatore. Both individuals bring deep communications and military expertise to Comtech’s satellite business line and will report to Daniel Gizinski who was named President of Comtech’s U.S. based satellite product line in January 2022.

Mr. Opalski will be responsible for driving operational excellence at both Comtech’s existing Santa Clara site and for the new state-of the-art Chandler, Arizona high-volume manufacturing and technology facility. Mr. Pescatore will lead the Satellite Network Technologies Digital Products Team in continuing development of industry leading satellite modems, network products, and cybersecurity support, ensuring flawless program execution and high customer satisfaction.

“Jon and Bob’s record of success and proven leadership skills make them highly qualified and ensure that we will strengthen our ability to serve government and commercial customers who have a need for integrated satellite-based solutions developed and manufactured in-house at facilities based in the United States,” said Michael Porcelain, CEO and President of Comtech.

About Jon
Opalski and Robert (“Bob”) Pescatore

Opalski joins Comtech from Benchmark Electronics, Inc. a multi-billion-dollar, world-class technology, engineering, and manufacturing service company that includes focus on next-generation technology and defense products. He served as General Manager of the Lark RF Technology Group where he oversaw a team of engineering and production personnel focused on RF/Microwave products. Opalski has also held several senior executive roles at REMEC Broadband Wireless Networks, including President and COO, where he managed hundreds of millions of dollars of RF and microwave solutions for the wireless telecom infrastructure market.

Pescatore joins Comtech from Cubic Corporation, a multi-billion-dollar defense company. At Cubic, Pescatore held a variety of executive level positions including Sr. Director of Halo Enterprise, Vice President and General Manager of Ground Training Solutions, Program Director for Air Ranges, and Business Development Director for Airborne Systems and Information Superiority. His earlier career was with the United States Marines Corps where he served 20 years as a Marine F/A 18 pilot.

About Comtech

Comtech Telecommunications Corp. is a leading global provider of next-generation 911 emergency systems and secure wireless communications technologies to commercial and government customers around the world. Headquartered in Melville, New York and with a passion for customer success, Comtech designs, produces and markets advanced and secure wireless solutions. For more information, please visit www.comtechtel.com (and preview its new website at www.comtech.com).

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results could differ materially from such forward-looking information. The Company’s Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such Securities and Exchange Commission filings.

PCMTL

View source version on 
businesswire.com: https://www.businesswire.com/news/home/20220601006312/en/

Contacts
Investor
 Relations
Robert Samuels
631-962-7102

robert.samuels@comtech.com

Source: Comtech Telecommunications Corp.


Release – Ayala Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare Conference

Posted on by Admin



Ayala Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare Conference

Research, News, and Market Data on Ayala Pharmaceuticals


REHOVOT, Israel and WILMINGTON, Del., June 02, 2022 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will participate in a “Fireside Chat” presentation at the Jefferies Healthcare Conference, to take place June 8-10, 2022, in New York, NY. The company will also be available for one-on-one meetings with institutional investors at the conference.

Details on the presentation can be found below:

Date:

Friday, June 10, 2022

Time:

12:15 – 12:40 PM EST

Format:

Fireside Chat

Location:

Marriott Marquis, 1535 Broadway, NYC

A webcast of the presentation will be available on the “Events and Presentations” section of the Ayala Pharmaceuticals website.

About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma-secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations. AL102 is currently in a Pivotal Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE) and is being evaluated in a Phase 1 clinical trial in combination with Novartis’ BMCA targeting agent, WVT078, in patients with relapsed/refractory Multiple Myeloma. For more information, visit 
www.ayalapharma.com.

Contacts:

Investors:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602

jallaire@lifesciadvisors.com

Ayala Pharmaceuticals:
+1-857-444-0553

info@ayalapharma.com


Baudax Bio (BXRX) – BX2000 Phase I First Cohort Dosed

Posted on by Admin

Thursday, June 02, 2022

Baudax Bio (BXRX)
BX2000 Phase I First Cohort Dosed

Baudax Bio is a pharmaceutical company focused on innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent specific to these NMBs. For more information, please visit www.baudaxbio.com.

Gregory Aurand, Senior Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Phase I Neuromuscular Blocking Agent (NMB) trial advances.  The BX2000 trial is a double-blind, placebo-controlled dose escalation study with up to 10 dosing cohorts. Each cohort will enroll 8 patients and the Company yesterday announced the first cohort has been dosed.  The study will evaluate safety, pharmacokinetics, and time course of the neuromuscular blocking profile.

Baudax Bio now has two novel NMBs in the clinic. BX1000 is a rapid onset, intermediate acting agent that has completed the dose escalation Phase I and is currently moving toward Phase II. BX2000 is a rapid onset, ultra-short acting agent with Phase I dose escalation enrollment expected to be completed by early 2023.

…

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – Comstock Announces Results of Annual Shareholders Meeting

Posted on by Admin



Comstock Announces Results of Annual Shareholders Meeting

Research, News, and Market Data on Comstock Mining


VIRGINIA
CITY, NEVADA, JUNE 2, 2022 – Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”) announced today that it had conducted its Annual Meeting of Shareholders on May 26, 2022, providing shareholders updates on the Company’s commercialization of decarbonization technologies and businesses, including the Company’s electrification (“LiNiCo”) and cellulosic fuels (“Bioleum™”) products.

Annual General Meeting

The Company’s Executive Chairman, Mr. Corrado De Gasperis, presided over the annual meeting, held in Reno, Nevada, and presented the Company’s new Vision, Mission and Goal, including a summary of the major differentiators in each of the Company’s decarbonization technologies and businesses. The meeting represented one of the largest shareholder turnouts.

Click
Here for Video

The meeting continued with presentations on the electrification and cellulosic fuels businesses.

Electrification Products

The Company announced the completion of its first pilot facility for breakthrough LIB crushing, separating, and conditioning process, and displayed the system’s ability for producing black mass during the annual meeting, successfully confirming LIB processing without discharge and the production of highly concentrated “black mass” powders. Demonstration models and product samples were available for viewing by all shareholders present at the meeting. The update was presented by the Company’s Chief Operating Officer, Mr. William McCarthy.

Click
Here for Video

The research and development facility will complete a series of remaining trials, with existing varieties of LIB batteries on hand, before being permanently deployed into LiNiCo’s state-of-the art battery recycling facility in Nevada later this year. 

“Our novel crushing and separating systems deliver a number of unique features enabling a broader range of LIB feedstocks that produce high purity black masses for a variety of downstream extraction processes,” said Corrado De Gasperis, Comstock’s executive chairman and chief executive officer. “The system is so versatile that we can manufacture large scale, centralized deployments and much smaller-scale, fast and profitable localized deployments.”

The Company is completing a modified air quality permit for its LIB processes at LiNiCo’s state-of-the-art recycling facility in Nevada, as well as the permit for its new battery storage and transfer facility in Nevada, for submission during this second quarter of 2022, and expects to receive all required permits, including the previously submitted permits, this year.

Cellulosic Fuels

The Company overviewed the competitive advantages of its cellulosic fuels technology as it pertained to variables such as availability of feedstocks for continuous growth, lower costs of feedstocks, enhanced carbon impact and resulting higher revenues, especially its expansion into Bioleum and its derivatives, drop in diesel, sustainable aviation and marine fuels, among others. The Company is currently expanding its existing cellulosic demonstration systems in Wisconsin to include the production of Bioleum. Demonstration models and product samples were available for viewing by all shareholders at the meetings.  The update was presented by the Company’s Chief Technology Officer, Mr. David Winsness.

Click
Here for Video

About
Comstock

Comstock (NYSE: LODE) innovates technologies that contribute to global decarbonization and circularity by efficiently converting under-utilized natural resources into renewable fuels and electrification products that contribute to balancing global uses and emissions of carbon. The Company intends to achieve exponential growth and extraordinary financial, natural, and social gains by building, owning, and operating a fleet of advanced carbon neutral extraction and refining facilities, by selling an array of complementary process solutions and related services, and by licensing selected technologies to qualified strategic partners. To learn more, please visit www.comstock.inc.

Forward-Looking
Statements 

This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements, but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future industry market conditions; future explorations or acquisitions; future changes in our exploration activities; future changes in our research and development; and future prices and sales of, and demand for, our products and services. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Neither this press release nor any related call or discussion constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund or any other issuer.

Contact information:

 

 

Comstock Mining Inc.
P.O. Box 1118
Virginia City, NV 89440
www.comstock.inc

Corrado De Gasperis
Executive Chairman & CEO
Tel (775) 847-4755
degasperis@comstockmining.com

Zach Spencer

Director of External Relations
Tel (775) 847-5272 Ext.151
questions@comstockmining.com